Natalizumab

PB006, the first biosimilar for natalizumab, showed comparable safety, efficacy and immunogenicity to the reference monoclonal antibody therapy in patients with relapsing-remitting MS, researchers wrote in JAMA Neurology.

Most patients with relapsing-remitting MS who are stable on natalizumab every 4 weeks, can switch to a 6-week dosing regimen without losing efficacy, according to results of a clinical trial published in the Lancet Neurology.

Pregnancy-related MS relapses were associated with early natalizumab withdrawal among women before and during pregnancy, according to a study published in JAMA Network Open.

Dimethyl fumarate and fingolimod appeared to have no significant difference in relapse rates, and rituximab appeared to have better relapse outcomes than natalizumab in patients with MS, according to results published in JAMA Network Open.

While we know women are threefold more likely than men to receive an MS diagnosis and they are usually diagnosed during their childbearing years, data on the impact of pregnancy on MS outcomes remain less clear.